Not provided
Not provided
Not provided
Not provided
Not provided
accrual was sufficient at interim analysis to draw final conclusions needed to publish
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Seinajoki Central Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
A randomized, prospective study to compare the direct and indirect costs, functional and oncologic results of 3D laparoscopic and robot assisted radical prostatectomy procedures.
The direct and indirect costs, functional and oncologic results of robot assisted radical prostatectomy (RALP) are compared to those of 3D laparoscopic radical prostatectomy. The hypothesis of the study is that the functional and oncologic results of the two operative methods are equal, but the direct costs of RAPL are significantly higher. A randomized, prospective non-inferiority study will will enroll 280 patients randomized 1:1 to both operative approaches to test this hypothesis. The primary functional outcome measure is the proportion of patients with complete urinary continence (no protective pad use) at 12 months post operatively. Secondary functional outcome measure is the preservation erectile function at 12 months post operatively. Oncologic outcome measures are the proportion of patients with undetectable post operative prostate specific antigen levels and positive surgical margins at pathological examination. The direct and indirect costs of both operative approaches are recorded.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Robot assisted prostatectomy. | Active Comparator | Intervention: radical prostatectomy |
|
| 3D laparoscopic prostatectomy | Experimental | Intervention: radical prostatectomy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Radical prostatectomy | Procedure | Surgical removal of the prostate |
|
| Measure | Description | Time Frame |
|---|---|---|
| Urinary continence | Expanded Prostate Cancer Index Composite (EPIC) Short Form (EPIC-26), urinary domain score is used to assess the return of continence post operatively. The percentage of patients with no protective pad use at 12 months post operatively is the main outcome measure. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Erectile function | International Index of Erectile Function (IIEF-5) Questionnaire score is used to quantify the return of erectile function post operatively. | 12 months |
| Prostate specific antigen |
| Measure | Description | Time Frame |
|---|---|---|
| costs of treatment | Direct and indirect treatment related costs. | 12 months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Antti Kaipia, M.D., Ph.D. | chief, dept of urology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tampere University Hospital | Tampere | 33521 | Finland |
Patient demographic, primary and secondary outcome measures available upon request.
2020 onward for 5 years.
IPD will be made for relevant high quality reseach uopn request.
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Prospective randomized study
Not provided
Not provided
Not provided
Not provided
Post operative prostate specific antigen levels.
| 12 months |
| Evaluation of surgical margins at pathologic examination. | The oncological outcome is evaluated by the presence of cancerous tissue at the surgical margins of the specimen at pathologic examination. | up to 12 months |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |